[1] Griffith DE, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. American Journal of Respiratory and Critical Care Medicine. 2007; 175(4):367-416.
[2] Strnad L, Winthrop KL. Treatment of Mycobacterium abscessus Complex. Semin. Respir. Crit. Care Med. 2018;39(3):362-76.
[3] Atsuyuki K. Diagnosis and treatment of Mycobacterium abscessus lung disease. Journal of Clinical and Experimental Medicine. 2014;248(10):792-8.
[4] Atsuyuki K. TREATMENT OF RELATIVELY RARE SPECIES NONTUBERCULOUS PULMONARY MYCOBACTERIOSIS. Kekkaku. 2011;86(12):923-32.
[5] Zelazny AM, et al. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J. Clin. Microbiol. 2009;47(7):1985-95.
[6] Lee MR, Sheng WH, Hung CC, Yu CJ, Lee LN, Hsueh PR. Mycobacterium abscessus complex infections in humans. Emerg. Infect. Dis. 2015;21(9):1638-46.
[7] Myojin S, et al. Chronic otitis media caused by Mycobacterium abscessus spp. massiliense treated with tigecycline in a 10-year-old child. Int. J. Infect. Dis. 2018;74:10-2.
[8] W. RJ, S. JM, S. VA, G. RC, T. JA, S. MS. Spectrum of disease due to rapidly growing mycobacteria. Rev. Infect. Dis. 1983;5(4).
[9] Wallace RJ, Brown BA, Griffith DE. NOSOCOMIAL OUTBREAKS / PSEUDO- OUTBREAKS CAUSED BY NONTUBERCULOUS MYCOBACTERIA. Annual Review of Microbiology. 1998;52:453-90.
[10] W. wai Yew, P. chuen Wong, H. sin Woo, C. wai Yip, C. yeung Chan, and F. bun Cheng. Characterization of Mycobacterium fortuitum isolates from sternotomy wounds by antimicrobial susceptibilities, plasmid profiles, and ribosomal ribonucleic acid gene restriction patterns. Diagn. Microbiol. Infect. Dis. 1993;17(2):111-7.
[11] H.M.El Sahly, et al. Mycobacterium simiae pseudo-outbreak resulting from a contaminated hospital water supply in Houston, Texas. Clin. Infect. Dis. 2002;35(7):802-7.
[12] Freitas D, et al. An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology. 2003;110(2):276-85.
[13] Osamu H, Chiyoko N.Various pathological conditions suggesting association of chronic epipharyngitis and the putative mechanism of epipharyngeal abrasive therapy. Japan Society of Stomato-Pharyngology. 2018;31(1):69-75.
[14] Yoshihiro O. Effectiveness of epipharyngeal abrasive therapy for chronic epipharyngitis. Japan Society of Stomato-Pharyngology. 2019;32(1),33-9.
[15] Hotta O, Inoue N, Tanaka A, Ieiri N. Possible Mechanisms Underlying Epipharyngeal Abrasive Therapy (EAT) with ZnCl2 Solution for the Treatment of Autoimmune Diseases and Functional Somatic Syndrome. J. Antivir. Antiretrovir. 2017;9(4).
[16] Chandra NS, et al. Cluster of Mycobacterium chelonae keratitis cases following laser in-situ keratomileusis. Am. J. Ophthalmol. 2001;132(6):819-30.
[17] Clegg HW, Foster MT, Sanders WE, Baine WB. Infection due to organisms of the Mycobacterium fortuitum complex after augmentation mammaplasty: Clinical and epidemiologic features. J. Infect. Dis. 1983;147(3):427-33.
[18] Wallace RJ, et al. Diversity and sources of rapidly growing mycobacteria associated with infections following cardiac surgery. J. Infect. Dis. 1989;159(4):708-16.
[19] Wallace RJ, Zhang Y, Brown BA, Fraser V, Mazurek GH, Maloney S. DNA large restriction fragment patterns of sporadic and epidemic nosocomial strains of Mycobacterium chelonae and Mycobacterium abscessus. J. Clin. Microbiol. 1993;31(10):2697-701.
[20] Lowry PW, et al. Mycobacterium chelonae Causing Otitis Media in an Ear-Nose-and-Throat Practice. N. Engl. J. Med. 1988;319(15):978-82.
[21] Hector JSR, Pang Y, Mazurek GH, Zhang Y, Brown BA, Wallace RJ. Large restriction fragment patterns of genomic Mycobacterium fortuitum DNA as strain-specific markers and their use in epidemiologic investigation of four nosocomial outbreaks. J. Clin. Microbiol. 1992;30(5):1250-5.
[22] Bolan G et al. Infections with mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers. J. Infect. Dis. 1985;152(5):1013-9.
[23] Falkinham JO. Nontuberculous mycobacteria in the environment. Clinics in Chest Medicine. 2002;23(3):529-51.
[24] Von Reyn CF, et al. Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya. J. Clin. Microbiol. 1993;31(12):3227-30.
[25] Griffith DE, Girard WM, Wallace RJ. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis. 1993;147(5):1271-8.
[26] Daisuke J, et al. A CASE OF INFECTION WITH MYCOBACTERIUM MASSILIENSE IN A PATIENT WHO HAD LONG-TERM UNTREATED MYCOBACTERIUM AVIUM COMPLEX PULMONARY DISEASE. Kekkaku. 2017;92(6).463-7.
[27] Wayne PA, et al. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved Standard. NCCLS. 2003;M24-A.
[28] Brown BA, Wallace RJ, Onyi G, Rosas VDE, Wallace RJ. Activities of Four Macrolides, Including Clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-Like Organisms. Antimicrob Agents Chemother. 1992;36(1):180-4.
[29] Swenson JM, Wallace RJ, Silcox VA, Thornsberry C. Antimicrobial Susceptibility of Five Subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 2000;28(6):807-11.
[30] Mary S, Christensen LA, Wallace RJ, Swenson JM, Thornsberry C. Agar Disk Elution Method for Susceptibility Testing of Mycobacterium marinum and Mycobacterium fortuitum Complex to Sulfonamides and Antibiotics. Antimicrob Agents Chemother. 1983;24(4).486-93.
[31] Wallace RJ, Brown BA, Onyi G. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the Two Subgroups of Mycobacterium chelonae to Imipenem, Cefmetazole, Cefoxitin, and Amoxicillin-Clavulanic Acid. Antimicrob Agents Chemother. 1991;35(4):773-5.
[32] Peloquin CA, et al. Aminoglycoside Toxicity : Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial Diseases. Clin Infect Dis. 2004;38:0-6.
[33] Wallace RJ, Brown, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis. 1992;166(2):405-12.
[34] Harada T, et al. Clinical and Microbiological Differences between Mycobacterium abscessus and Mycobacterium massiliense Lung Diseases. J Clin Microbiol. 2012;50(11):3556-61.
[35] Lyu J, et al. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. Respir. Med. 2014;108(11):1706-12.
[36] Park J, Cho J, Lee CH, Han SK, Yim JJ. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis. 2017;64(3):301-8.
[37] The Japanese Society for Tuberculosis and Nontuberculous Mycobateriosis. Acid-fast bacillus test guide. NANKODO. 2016. 122p.
[38] Koh W, et al. Clinical Significance of Differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011;183(3):405-10.